Casa di Cura del Policlinico
Milan, MI, 20144, Italy
NCT Number: NCT05538455
Personalized Integrated Care Promoting Quality of Life for Elderly People (ProCare4Life, PC4L) project was created to finalize a digital platform with integrated sensors , for monitoring the health status of the elderly subjects with neurodegenerative diseases and comorbidities.
In fact, an integrated care platform - able to establish correlations between comorbidities, investigate the intake of different drugs, mitigate potential health risks, study the social variables and promote unified therapeutic procedures or social services - could help patients, caregivers, healthcare professionals and social health workers to monitor various diseases parameters.
The main contribution of the PC4L project is to propose an integrated, scalable and interactive care system that can be easily adapted to the reality of various chronic diseases, care institutions and end-user needs, for the benefit of all the actors involved. The main expected results are to improve patients' quality of life, enable an active life and better disease management, support professionals in decision making, facilitate efficient communication between all stakeholders and ensure reliable and secure access to data at the within Europe.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Milan, MI, 20144, Italy
There is an urgent need to increase the efficiency and sustainability of health and social care systems across Europe, as there is a growing trend in public spending, which is expected to reach 14% of GDP by 2030. The main causes are the aging of the population, and the increase of chronic diseases, including cardiovascular diseases, diabetes, asthma, mental and physical disorders and neurodegenerative conditions. Comorbidities and the confluence of various chronic diseases is increasingly common in the elderly, which increases the need to develop models and tools to improve integrated health systems.
Population aging has also led to major reforms in long-term care policies and systems in many European countries, increasing the need for alternatives. This implies the need for help with housework or other practical errands, transportation by doctors or social visits, social companionship, emotional guidance, or help in organizing professional care. In most European countries, much of the care people over 60 receive is informal care.
Among the most common chronic diseases in the elderly population, neurocognitive deterioration in the stages of dementia associated with Alzheimer's and Parkinson's are the most disabling. Today, more than 10 million Europeans live with neurocognitive disorders in stages of dementia.
This situation can be improved through the creation of an integrated care platform, able to establish correlations between co-morbidities, investigate the use of the intake of different drugs, mitigate potential health risks, study the social variables involved and promote unified therapeutic procedures or social services. This solution could help patients, health professionals and social health workers to monitor various diseases, also considering the social context. In addition, people with chronic diseases face difficulties in their daily life and need specialized care services and care. This situation imposes high burdens on the public budget, which require particular attention to adequately address the sustainability of the social and health system in Europe.
The main contribution of the PC4L project is to propose an integrated, scalable and interactive care system that can be easily adapted to the reality of various chronic diseases, care institutions and end-user needs, for the benefit of all the actors involved (e.g. patients, caregivers and health experts). The main expected results are to improve patients' quality of life, enable an active life and better disease management, support professionals in decision making, facilitate efficient communication between all stakeholders and ensure reliable and secure access to data at the within Europe.This study is part of the European multicenter project Horizon 2020, called Personalized Integrated Care Promoting Quality of Life for Elderly People (ProCare4Life, PC4L), which involves several European partners and was created with the aim of finalizing a digital platform with integrated sensors, aimed at home monitoring of health status and treatment of the elderly patient with Parkinson's disease or Alzheimer's disease and other dementias.The PC4L Project was funded by the European Community Horizon 2020 innovation and research program (grant agreement No 875221), for the development of an international research project aimed at exploring the potential of assistive technologies in monitoring the behavior of elderly subjects. The project involves in fact the elderly population suffering from chronic neurological diseases and other comorbidities such as diabetes mellitus and arthritis. This project also aims to provide home support to the caregivers of subjects affected by these diseases.
PC4L-Pilot3 represents the third and last large-scale pilot study within the project, where the first one was aimed to explore feasibility and usability of the solution, and the second one investigated the characteristics of the metrics generated by the PC4L platform in real-life conditions.
In this pilot study, six clinical centers are involved, in five different European countries (Italy, Spain, Portugal, Romania, Germany), operating in the neurological context both at hospital and home care, as well as daycare centers.
An interventional, multicenter, randomized controlled trial will be conducted. The duration of the study per patient at home will be 3 months. Participants admitted to rehabilitation and daycare centers will use the PC4L platform for the entire duration of their stay in the center (not exceeding the 3 months).
Patients will be randomized into two groups: experimental group, which will use the PC4L platform for the duration envisaged by the study and will receive notifications and recommendations from the system; and the control group, which will follow the recommendations in paper form for the period envisaged by the study. Caregivers and health professionals will also be involved.
In-person assessments will take place at baseline and at the end of the study (3-month follow-up or at discharge from the rehabilitation/daycare program).
Demographic and clinical data (age, gender, level of education, professional activity, social support, previous use of technology) will be assesed at baseline. In-person assessments thorugh clinical evaluation will take place at baseline and at the end of the study (3-month follow-up or at discharge from the rehabilitation/daycare program). Clinical assessments are the following:
MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Clinical Dementia Rating Scale (CDRS); Falls Self-Efficacy Scale (FES-I); Berg Balance test; Pittsburgh Sleep quality index score: State-Trait-Anxiety-Inventory (STAI); presence of festination, dysphasia, wandering episodes (last month); EuroQol5D3L; Barthel Index; patient satisfaction and empowerment (PACIC, SAPS); non-programmed medical resources used (last month); Cumulative Illness Rating Scale-Geriatric (CIRS-G) ; adverse events reporting; System Usability Scale (SUS) ; end-of-study survey (Global satisfaction with a 5-point Likert scale; What do you like most/least? Suggestions); end-of-study open questions (Which type of recommendations have you been using? How did you find the recommendations? how it helped in improving your wellbeing? What did you like the most/least?).
The PROCare4Life ecosystem consists of:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
Time frame: up to three months
Improvement of the quality of life in the 'experimental' group of patients who use the PC4L platform for a period of three months, compared to the control group, equal to 10% according to the scale EuroQol5D3L: the primary outcome of the study will be the difference in quality of life between groups, measured by the EuroQol5D3L scale at the end of the study.
Sample size calculation was based on a previous study (Fan X, et al. Assessment of Health-Related Quality of Life between People with Parkinson's Disease and Non-Parkinson's: Using Data Drawn from the '100 for Parkinson's' Smartphone-Based Prospective Study. Int J Environ Res Public Health. 2018) that compared the quality of life of two groups of patients. It was estimated that a total of 558 patients, 279 per study group, will be necessary to achieve an improvement of 10% in EuroQol5D3L, with 95% power.
Time frame: up to three months
Change in the score of MDS-UPDRS measured at baseline and at the end of the study. Higher scores mean worse outcome.
Time frame: up to three months
Change in the score of CDRS measured at baseline and at the end of the study. It yields a single score on a scale of 0-5, where higher scores mean worse outcome.
Time frame: up to three months
Change in the score of FES-I measured at baseline and at the end of the study. It yields a single score on a scale of 16-64, where higher scores mean worse outcome.
Time frame: up to three months
Change in the score of PSQI measured at baseline and at the end of the study. It yields a single score on a scale of 0-21, where higher scores mean worse outcome.
Time frame: up to three months
Change in the score of STAI measured at baseline and at the end of the study. It yields a single score on a scale of 20-80, where higher scores mean worse outcome.
Time frame: up to three months
Change in the score of BI measured at baseline and at the end of the study. It yields a single score on a scale of 0-100, where higher scores mean better outcome.
Time frame: up to three months
Change in the score of PACIC measured at baseline and at the end of the study. It yields a single score on a scale of 0-5, where higher scores mean better outcome.
Time frame: up to three months
Change in the score of SAPS measured at baseline and at the end of the study. It yields a single score on a scale of 0-28, where higher scores mean better outcome.
Time frame: up to three months
Change in the score of CIRS-G measured at baseline and at the end of the study .
It yields a single score on a scale of 0-56, where higher scores mean worse outcome.
Time frame: up to three months
SUS is used to measure how easy or difficult the proposed system is to use. We will compare the usability of two different versions of the PC4L system (fully equipped and cloud-based solution).
It yields a single score on a scale of 0-100, where higher scores mean better outcome.
Casa di Cura Privata del Policlinico SpA
Other
ProCare4Life Pilot 3 Clinical Study: Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07545473
Alzheimer Disease, Arterial Occlusive Diseases
Melbourne, Victoria, Australia
View Trial DetailsNCT06869135
Alzheimer Disease, Basal Ganglia Diseases
Florence, FI, Italy
View Trial DetailsNCT06596746
Alzheimer Disease, Amyotrophic Lateral Sclerosis
Cassino, Frosinone, Italy
View Trial DetailsNCT06209515
Alzheimer Disease, Amyotrophic Lateral Sclerosis
Kuopio, Finland
View Trial Details